Phathom Pharmaceuticals, Inc.·Healthcare

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NY Date: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare Conference Date: Wednesday, April 15, 2026Fireside Chat: 1:30 pm EDT Management to participate in one-on-one meetings throughout the conference To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.

Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16.

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.79 per share a year ago.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Healthcare
Biotechnology
427
2019-10-25
0.61